FibroBiologics Appoints Ruben A. Garcia as General Counsel

HOUSTON, March 6, 2024 /PRNewswire/ -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 150+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, announced the appointment of Ruben A. Garcia as General Counsel. He will report to Pete O'Heeron, FibroBiologics' Founder, Chairman and Chief Executive Officer, and be an integral member of the executive leadership team.  

"The addition of Ruben as our General Counsel represents a significant milestone for FibroBiologics in its journey as a publicly traded company," said Mr. O'Heeron. "His experience, particularly in public company reporting and corporate governance matters, healthcare compliance, and strategic and commercial transactions, is a key addition. We believe Ruben's appointment will enhance FibroBiologics' overall leadership and organizational efficiency as well as help us advance our clinical and pre-clinical pipelines." 

"I am thrilled and honored to become a part of this extraordinary team," said Mr. Garcia. "Arriving at such a pivotal moment, I am confident that our collective capabilities and vision will elevate FibroBiologics well." 

Mr. Garcia brings more than 20 years of experience and an extensive background in legal leadership positions in the pharmaceutical industry. He most recently served as Senior Vice President, General Counsel and Corporate Secretary at AcelRx Pharmaceuticals, Inc. (n/k/a Talphera, Inc.). In that role, he was responsible for all legal and compliance matters. Prior to his role at AcelRx, Mr. Garcia served as Senior Corporate Counsel and Assistant Secretary for Ultragenyx Pharmaceutical Inc. Mr. Garcia began his legal career at Vinson & Elkins L.L.P. in Houston before joining Jones Day in Silicon Valley. He earned his Juris Doctor from Stanford Law School and his B.A. from Georgetown University. Mr. Garcia is a member of the State Bars of California and Texas. 

For more information, please visit FibroBiologics' website or email FibroBiologics at: [email protected].  

Cautionary Statement Regarding Forward-Looking Statements 

This communication contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements include information concerning FibroBiologics' advancement of its pipelines and the role to be played by, and impact of, the General Counsel. These forward-looking statements are based on FibroBiologics' management's current expectations, estimates, projections and beliefs, as well as a number of assumptions concerning future events. When used in this communication, the words "estimates," "projected," "expects," "anticipates," "forecasts," "plans," "intends," "believes," "seeks," "may," "will," "should," "future," "propose" and variations of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements. These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside FibroBiologics' management's control, that could cause actual results to differ materially from the results discussed in the forward-looking statements, including those set forth under the caption "Risk Factors" and elsewhere in FibroBiologics' annual, quarterly and current reports (i.e., Form 10-K, Form 10-Q and Form 8-K) as filed or furnished with the SEC and any subsequent public filings. Copies are available on the SEC's website, www.sec.gov. These risks, uncertainties, assumptions and other important factors include, but are not limited to: (a) the ability of FibroBiologics to continue to meet Nasdaq listing requirements; (b) risks related to FibroBiologics' liquidity and its ability to maintain capital resources sufficient to conduct its business; and (c) the ability to effectively manage the business as a result of the super-voting proxy given to the Board of Directors. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and FibroBiologics assumes no obligation and, except as required by law, does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. FibroBiologics gives no assurance that it will achieve its expectations. 

About FibroBiologics
Based in Houston, FibroBiologics is a cell therapy, regenerative medicine company developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. FibroBiologics holds 150+ US and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer. FibroBiologics represents the next generation of medical advancement in cell therapy. For more information, visit www.FibroBiologics.com. 

General Inquiries:
[email protected] 

Investor Relations:
Nic Johnson or Harrison Seidner, Ph.D.
Russo Partners
212-845-4242
[email protected] 

Media Contact:
Liz Phillips
Russo Partners
(347) 956-7697
[email protected]  

SOURCE FibroBiologics